- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01700751
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Missouri
-
Saint Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patient must be scheduled to undergo stem cell transplantation for one of the following diagnoses:
- acute myeloid leukemia (AML) in CR1 (first complete remission, CR or CRi) or CR2 (second complete remission, CR or CRi),
- acute lymphoblastic leukemia (ALL) in CR1 or CR2 (CR or CRi)
- myelodysplastic syndrome (MDS) without progression to AML.
- Chronic myelogenous leukemia (CML)
- Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD)
- Chronic lymphocytic leukemia (CLL)
- Multiple myeloma (MM)
- Patients must be the recipient of unrelated donor peripheral blood stem cell products. Mismatches at both antigen and allele level will be eligible. Match must be 6 or 7 out of 8 loci (HLA A, B, C, and DRB1).
- Patient must receive any one of the following conditioning regimens: total body radiation (single or fractionated dose)/cyclophosphamide, busulfan/ cyclophosphamide, or fludarabine/busulfan/lymphocyte immune globulin (ATGAM/thymo).
- Patient must be ≥ 18 years and ≤ 70 years of age.
- Patient must have an ECOG performance status ≤ 2 or Karnofsky performance scale ≥ 60%
- Patient must have CD34+ stem cells ≥ 2x106/kg (actual body weight of the recipient) available for transplantation.
Patient must have appropriate organ function as defined below (this criterion should be met on screening and on the day of the first dose of brentuximab vedotin (as assessed prior to dosing)):
- Total bilirubin ≤ 2.0 x IULN
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Serum creatinine ≤ 2.0 x IULN
- Estimated Creatinine Clearance > 30 ml/min
- Cardiac ejection fraction > 40%
- DLCO/VA > 40%
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Patient must be able to understand and willing to sign an IRB approved written informed consent document.
Exclusion Criteria:
- Patient must not have had prior exposure to brentuximab vedotin.
- Patient must not have a history of other malignancy that has not been in remission for at least 3 years, with the exception of basal non-melanoma skin cancer which were treated with local resection only or intraepithelial lesions or carcinoma in situ of the cervix or prostate that has been curatively treated.
- Patient must not be receiving any other investigational agents.
- Patient must not have active CNS involvement.
- Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin or other agents used in the study.
- Patients must not have had previous radiation therapy to the mediastinum or lungs.
- Patient must not have an uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active pulmonary diseases, or psychiatric illness/social situations that would limit compliance with study requirements (this criterion should be met on screening and on the day of but prior to first dose of brentuximab vedotin).
- Patient must not be pregnant and/or breastfeeding.
- Patient must not be known to be HIV-positive on combination antiretroviral therapies.
- Patient must not have had a previous allogeneic or syngeneic transplant. Prior autologous transplant is allowed.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Dose Level 0 (starting dose)
brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
|
Andre navn:
|
Eksperimentell: Dose Level 1
brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
|
Andre navn:
|
Eksperimentell: Dose Level 2
brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
|
Andre navn:
|
Eksperimentell: Dose Level 3
brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
|
Andre navn:
|
Ingen inngripen: Control Dose Level
The first 3 patients will not receive brentuximab vedotin.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
MTD of brentuximab vedotin when administered with a GVHD prophylaxis regimen
Tidsramme: 37 days
|
Defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity; Hematologic DLT is defined as ANC < 500/mm3 for three consecutive days beyond Day +21 that was determined by the investigator to be likely related to brentuximab vedotin. Non-hematologic DLT is defined as any grade 3 or higher non-hematologic toxicity that was determined by the investigator to be possibly, probably, or definitely related to brentuximab vedotin, with the following specific exceptions:
|
37 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Safety and tolerability of brentuximab vedotin when administered with a GVHD prophylaxis regimen
Tidsramme: 100 days
|
Toxicities described and graded using CTCAE version 4.0; described by patient, type, and grade for each dose level; summarized by counts and percentage of patients in the corresponding categories
|
100 days
|
Rate of acute GVHD
Tidsramme: 100 days
|
Proportion of all subjects who experience symptoms consistent with grade 2-4 acute GVHD; using the standard grading system adapted from the Glucksberg clinical stage and grade of acute GVHD
|
100 days
|
Rate of chronic GVHD
Tidsramme: 2 years
|
Proportion of all subjects who experience symptoms consistent with chronic GVHD; assessment will begin after Day 100 using the NIH consensus criteria for diagnosis and staging of chronic GVHD
|
2 years
|
Progression-free survival
Tidsramme: 2 years
|
Duration from the time of transplant to time of first progression, death, relapse after complete response, or the date the patient was last known to be in remission; estimated with Kaplan-Meier methods.
|
2 years
|
Overall survival.
Tidsramme: 2 years
|
Duration from the time of transplant to death or last follow-up; estimated with Kaplan-Meier methods.
|
2 years
|
1-year non-relapse mortality rate
Tidsramme: 1 year
|
Defined as the percentage of patients dying from etiologies other than disease relapse; estimated with Kaplan-Meier methods.
|
1 year
|
2-year non-relapse mortality rate
Tidsramme: 2 years
|
Defined as the percentage of patients dying from etiologies other than disease relapse; estimated with Kaplan-Meier methods.
|
2 years
|
1-year disease relapse rate
Tidsramme: 1 year
|
Defined as the percentage of patients who have disease relapse; estimated with Kaplan-Meier methods.
|
1 year
|
2-year disease relapse rate
Tidsramme: 2 years
|
Defined as the percentage of patients who have disease relapse; estimated with Kaplan-Meier methods.
|
2 years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesykdommer
- Immunproliferative lidelser
- Benmargssykdommer
- Hematologiske sykdommer
- Leukemi, lymfoid
- Leukemi, myeloid
- Myelodysplastiske syndromer
- Leukemi
- Leukemi, Myeloid, Akutt
- Forløpercelle lymfoblastisk leukemi-lymfom
- Antineoplastiske midler
- Antineoplastiske midler, immunologiske
- Brentuximab Vedotin
Andre studie-ID-numre
- 201211047
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Myelodysplastiske syndromer
-
M.D. Anderson Cancer CenterHar ikke rekruttert ennåMyeloproliferativ neoplasma | Myelodysplastisk neoplasma | Pathway Mutant Myelodysplastic SyndromeForente stater
-
University of Colorado, DenverRekrutteringKlinefelters syndrom | Trisomi X | XYY syndrom | XXXY og XXXXY syndrom | Xxyy syndrom | Xyyy syndrom | Xxxx syndrom | Xxxxx syndrom | Xxxyy syndrom | Xxyyy syndrom | Xyyyy syndrom | Mann med sexkromosommosaikkForente stater
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.FullførtTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapierelatert myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært høyrisiko myelodysplastisk syndromForente stater
-
Assistance Publique - Hôpitaux de ParisRekrutteringIntensivavdelingens syndrom | Pediatrisk postintensiv syndromFrankrike
-
University of NottinghamMedical Research Council; National Institute for Health Research, United...RekrutteringSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromStorbritannia
-
Hospital Universitario GetafeKarolinska Institutet; Medical University of Lodz; Universidad Politecnica... og andre samarbeidspartnereUkjentSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromPolen, Spania, Sverige
-
Shaare Zedek Medical CenterUkjentPremenstruelt syndrom - PMS
-
Esra ÖZERKTO Karatay UniversityRekrutteringPremenstruelt syndrom - PMSTyrkia
-
Geriatric Education and Research InstituteSingapore General Hospital; Changi General Hospital; Sengkang General Hospital og andre samarbeidspartnereFullførtSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromSingapore
-
Brigham and Women's HospitalAktiv, ikke rekrutterendeSkrøpelig eldre syndrom | Skrøpelighet | Aldring | Skrøpelighet syndromForente stater
Kliniske studier på brentuximab vedotin
-
University Hospital, CaenRekruttering
-
Samsung Medical CenterMillennium Pharmaceuticals, Inc.FullførtNon-Hodgkin lymfomKorea, Republikken
-
Seagen Inc.Millennium Pharmaceuticals, Inc.FullførtLymfom, Non-Hodgkin | Lymfom, storcellet, anaplastisk | Sykdom, HodgkinForente stater, Frankrike
-
Seagen Inc.AvsluttetSystemisk lupus erythematosusForente stater
-
TG Therapeutics, Inc.FullførtHodgkins lymfomForente stater
-
Seagen Inc.Millennium Pharmaceuticals, Inc.Ikke lenger tilgjengeligLymfom, Non-Hodgkin | Lymfom, T-celle, kutan | Lymfom, storcellet, anaplastisk | Sykdom, HodgkinForente stater, Storbritannia, Belgia, Serbia, Australia, Bulgaria, Frankrike, Tyskland, Ungarn, Italia, Polen, Romania, Den russiske føderasjonen, Spania, Sveits
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterFullførtResidiverende eller refraktære EBV- og CD30-positive lymfomerKorea, Republikken
-
University of Modena and Reggio EmiliaMillennium Pharmaceuticals, Inc.Ukjent
-
Seagen Inc.Millennium Pharmaceuticals, Inc.FullførtLymfom, Non-Hodgkin | Lymfom, storcellet, anaplastisk | Sykdom, HodgkinForente stater, Tyskland
-
Fondazione Italiana Linfomi ONLUSFullførtTilbakefallende/Refraktær Hodgkins lymfomItalia